Kenneth J O'byrne

List of Publications by Year
in descending order

352 papers	37,365 citations	6613 79 h-index	3407 183 g-index
363 all docs	363 docs citations	363 times ranked	36816 citing authors

#	Article	IF	Citations
1	Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesotheliomaâ€"a phase 3 randomised trial. BMJ Open, 2022, 12, e057663.	1.9	9
2	First-line nivolumabÂ+ ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. ESMO Open, 2022, 7, 100394.	4.5	7
3	Clinical Applications of Circulating Tumour Cells and Circulating TumourÂDNA in Non-Small Cell LungÂCancerâ€"An Update. Frontiers in Oncology, 2022, 12, 859152.	2.8	15
4	Pembrolizumab-induced toxic epidermal necrolysis: case report. Oxford Medical Case Reports, 2022, 2022, omac025.	0.4	6
5	Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 2022, 29, 3044-3060.	2.2	239
6	Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas. Frontiers in Immunology, 2022, 13, .	4.8	2
7	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clinical and Translational Immunology, 2022, 11, .	3.8	10
8	Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.. Journal of Clinical Oncology, 2022, 40, 9517-9517.	1.6	11
9	Reducing pre-analytical sample QC failure rates for cancer molecular genetic assays with SLIMamp technology.. Journal of Clinical Oncology, 2022, 40, e15034-e15034.	1.6	0
10	Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer. Heliyon, 2022, 8, e09971.	3.2	4
11	Understanding the tumor microenvironment for effective immunotherapy. Medicinal Research Reviews, 2021, 41, 1474-1498.	10.5	130
12	Effects of HER Familyâ€"targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. Clinical Cancer Research, 2021, 27, 807-818.	7.0	34
13	COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target. Cancers, 2021, 13, 830.	3.7	3
14	Barrier-to-autointegration-factor (Banf1) modulates DNA double-strand break repair pathway choice via regulation of DNA-dependent kinase (DNA-PK) activity. Nucleic Acids Research, 2021, 49, 3294-3307.	14.5	13
15	Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy. Frontiers in Cell and Developmental Biology, 2021, 9, 633305.	3.7	40
16	Spatial profiling technologies and applications for brain cancers. Expert Review of Molecular Diagnostics, 2021, 21, 323-332.	3.1	12
17	Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 615967.	2.8	6
18	Tumor Hypoxia Drives Genomic Instability. Frontiers in Cell and Developmental Biology, 2021, 9, 626229.	3.7	21

#	Article	IF	Citations
19	Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. Cancers, 2021, 13, 2139.	3.7	6
20	First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. Journal of Thoracic Oncology, 2021, 16, 665-676.	1.1	30
21	Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. Translational Oncology, 2021, 14, 101025.	3.7	12
22	Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer. NAR Cancer, 2021, 3, zcab022.	3.1	4
23	COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks. Communications Biology, 2021, 4, 484.	4.4	8
24	MicroRNA expression profiling and biomarker validation in treatment-naÃ¯ve and drug resistant non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 1773-1791.	2.8	7
25	Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy. Communications Biology, 2021, 4, 638.	4.4	12
26	Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?. , 2021, 9, e002248.		35
27	Do ethnic patients report longer lung cancer intervals than Angloâ€Australian patients?: Findings from a prospective, observational cohort study. European Journal of Cancer Care, 2021, 30, e13492.	1.5	2
28	Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review. Frontiers in Molecular Biosciences, 2021, 8, 685440.	3.5	17
29	The Pandoraâ€™s box of novel technologies that may revolutionize lung cancer. Lung Cancer, 2021, 159, 34-41.	2.0	12
30	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2021, 21, 1165-1178.	3.1	20
31	Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 4651.	3.7	5
32	The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer, 2021, 160, 73-77.	2.0	6
33	hSSB2 (NABP1) is required for the recruitment of RPA during the cellular response to DNA UV damage. Scientific Reports, 2021, 11, 20256.	3.3	6
34	The Impact of Rare Human Variants on Barrier-To-Auto-Integration Factor 1 (Banf1) Structure and Function. Frontiers in Cell and Developmental Biology, 2021, 9, 775441.	3.7	8
35	Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics. Frontiers in Cell and Developmental Biology, 2021, 9, 801200.	3.7	25
36	Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC). Frontiers in Oncology, 2021, 11, 798296.	2.8	20

#	Article	IF	Citations
37	The Role of Circulating Biomarkers in Lung Cancer. Frontiers in Oncology, 2021, 11, 801269.	2.8	17
38	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptorâ€"Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. JAMA Oncology, 2020, 6, 100.	7.1	68
39	Prior or concurrent radiotherapy and nivolumab immunotherapy in nonâ€"small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 56-62.	1.1	10
40	Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab. Oxford Medical Case Reports, 2020, 2020, omaa077.	0.4	8
41	Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1795-1809.	2.8	24
42	The evolving landscape of predictive biomarkers in immunoâ€oncology with a focus on spatial technologies. Clinical and Translational Immunology, 2020, 9, e1215.	3.8	23
43	High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC). Cancers, 2020, 12, 3551.	3.7	26
44	The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. Frontiers in Oncology, 2020, 10, 1256.	2.8	33
45	Circulating tumor cell clusters: Insights into tumour dissemination and metastasis. Expert Review of Molecular Diagnostics, 2020, 20, 1139-1147.	3.1	18
46	SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. Scientific Reports, 2020, 10, 18605.	3.3	16
47	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncology, The, 2020, 21, 1213-1223.	10.7	109
48	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Frontiers in Cell and Developmental Biology, 2020, 8, 564601.	3.7	315
49	Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer. Lung Cancer Management, 2020, 9, LMT38.	1.5	9
50	The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells. Cells, 2020, 9, 1465.	4.1	14
51	Durable complete response to immunotherapy in treatmentâ€resistant metastatic colorectal cancer with thyroid transcription factor 1 expression. ANZ Journal of Surgery, 2020, 90, E97-E99.	0.7	0
52	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. Journal of Translational Medicine, 2020, 18, 99.	4.4	12
53	Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients. Frontiers in Oncology, 2020, 10, 607349.	2.8	22
54	Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer. British Journal of Cancer, 2020, 123, 591-603.	6.4	13

#	Article	IF	Citations
55	Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets. Current Medicinal Chemistry, 2020, 27, 1901-1921.	2.4	10
56	Targeting NF-Î¹B-mediated inflammatory pathways in cisplatin-resistant NSCLC. Lung Cancer, 2019, 135, 217-227.	2.0	25
57	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology, 2019, 51, 673-680.	0.6	8
58	Nivolumab plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2019, 381, 2020-2031.	27.0	1,866
59	Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 620.	3.7	9
60	Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncology, 2019, 15, 2287-2302.	2.4	42
61	Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. Cancers, 2019, 11, 548.	3.7	19
62	Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets. Cancers, 2019, 11, 380.	3.7	33
63	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Frontiers in Endocrinology, 2019, 10, 89.	3.5	10
64	First-Line Nivolumab Plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Journal of Clinical Oncology, 2019, 37, 992-1000.	1.6	457
65	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 2019, 132, 126-131.	2.0	26
66	Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel. Microsystems and Nanoengineering, 2019, 5, 8.	7.0	138
67	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1569-1579.	2.5	31
68	Targeting BRAF mutations in non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 1119-1124.	2.8	65
69	Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage. Nature Communications, 2019, 10, 5501.	12.8	40
70	Digital Holographic Imaging as a Method for Quantitative, Live Cell Imaging of Drug Response to Novel Targeted Cancer Therapies. Methods in Molecular Biology, 2019, 2054, 171-183.	0.9	9
71	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. New England Journal of Medicine, 2018, 378, 2093-2104.	27.0	2,469
72	BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Letters, 2018, 428, 117-126.	7.2	69

#	Article	IF	Citations
73	Development and characterisation of a panel of phosphatidylinositide 3-kinase â€“ mammalian target of rapamycin inhibitor resistant lung cancer cell lines. Scientific Reports, 2018, 8, 1652.	3.3	9
74	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer, 2018, 19, e465-e479.	2.6	56
75	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient, 2018, 11, 131-141.	2.7	20
76	The prognostic significance of circulating tumor cells in head and neck and nonâ€smallâ€cell lung cancer. Cancer Medicine, 2018, 7, 5910-5919.	2.8	91
77	Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1784-1791.	1.1	75
78	Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Frontiers in Oncology, 2018, 8, 92.	2.8	506
79	EV, Microvesicles/MicroRNAs and Stem Cells in Cancer. Advances in Experimental Medicine and Biology, 2018, 1056, 123-135.	1.6	5
80	The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer. Frontiers in Oncology, 2018, 8, 311.	2.8	94
81	Tissue and Blood Biomarkers in Lung Cancer: A Review. Advances in Clinical Chemistry, 2018, 86, 1-21.	3.7	85
82	Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. Scientific Reports, 2017, 7, 42517.	3.3	69
83	Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. International Journal of Oncology, 2017, 50, 1044-1052.	3.3	12
84	Nucleolar caspase-2: Protecting us from DNA damage. Journal of Cell Biology, 2017, 216, 1521-1523.	5.2	3
85	Expression of CDCA3 Is a Prognostic Biomarker andÂPotential Therapeutic Target in Nonâ€“Small CellÂLungÂCancer. Journal of Thoracic Oncology, 2017, 12, 1071-1084.	1.1	59
86	A Rare Case of Omentum Invasive Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, e311-e312.	1.3	13
87	OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7. Journal of Thoracic Oncology, 2017, 12, S335-S336.	1.1	1
88	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. British Journal of Cancer, 2017, 116, 175-185.	6.4	76
89	Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Nonâ€“Small-Cell Lung Cancer: METLung. Journal of Clinical Oncology, 2017, 35, 412-420.	1.6	237
90	Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2017, 12, 1626-1635.	1.1	81

#	Article	IF	Citations
91	Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. Cellular Immunology, 2017, 319, 35-42.	3.0	27
92	Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 277-288.	1.1	36
93	hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases. DNA Repair, 2017, 54, 30-39.	2.8	15
94	Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer, 2017, 83, 302-312.	2.8	18
95	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology, 2017, 28, 270-277.	1.2	425
96	hSSB1 associates with and promotes stability of the BLM helicase. BMC Molecular Biology, 2017, 18, 13.	3.0	10
97	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 3449-3457.	1.6	311
98	Impact and correlation of mutational load (ML) and specific mutations (mts) assessed by limited targeted profiling (LTP) with PD-L1 tumour expression (exp) in resected non-small cell lung carcinoma (NSCLC).. Journal of Clinical Oncology, 2017, 35, 11587-11587.	1.6	2
99	Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.. Journal of Clinical Oncology, 2017, 35, 8514-8514.	1.6	14
100	NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.. Journal of Clinical Oncology, 2017, 35, TPS9097-TPS9097.	1.6	5
101	Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. PLoS ONE, 2017, 12, e0184922.	2.5	54
102	Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. Oncotarget, 2017, 8, 72544-72563.	1.8	60
103	A structural analysis of DNA binding by hSSB1 (NABP2/OBFC2B) in solution. Nucleic Acids Research, 2016, 44, 7963-7973.	14.5	26
104	In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC. Oncotarget, 2016, 7, 79526-79543.	1.8	23
105	Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model. Scientific Reports, 2016, 6, 18907.	3.3	6
106	68P Inflammatory meditated mechanisms of cisplatin resistance in non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S84.	1.1	0
107	24P CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S65.	1.1	5
108	138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). Journal of Thoracic Oncology, 2016, 11, S116-S117.	1.1	2

#	Article	IF	Citations
109	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncology, The, 2016, 17, 577-589.	10.7	950
110	Targeting the fibroblast growth factor receptor family in cancer. Cancer Treatment Reviews, 2016, 46, 51-62.	7.7	99
111	Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo. BMC Cancer, 2016, 16, 707.	2.6	69
112	Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Annals of Oncology, 2016, 27, 2103-2110.	1.2	159
113	Nucleophosmin: from structure and function to disease development. BMC Molecular Biology, 2016, 17, 19.	3.0	189
114	How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?. Lung Cancer, 2016, 100, 5-13.	2.0	12
115	Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response. Cell Death and Disease, 2016, 7, e2469-e2469.	6.3	22
116	hSSB1 (NABP2/OBFC2B) is regulated by oxidative stress. Scientific Reports, 2016, 6, 27446.	3.3	31
117	Convenor's Welcome. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 3-3.	1.1	0
118	Novel insight into the composition of human single-stranded DNA-binding protein 1 (hSSB1)-containing protein complexes. BMC Molecular Biology, 2016, 17, 24.	3.0	9
119	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Future Oncology, 2016, 12, 1805-1822.	2.4	6
120	70P Identification of a novel microRNA signature: Potential diagnostic biomarkers and predictors of cisplatin response?. Journal of Thoracic Oncology, 2016, 11, S85.	1.1	1
121	74P Elucidating drug resistance mechanisms using 2D and 3D culture systems. Journal of Thoracic Oncology, 2016, 11, S86-S87.	1.1	0
122	Lung cancer stem cells: The root of resistance. Cancer Letters, 2016, 372, 147-156.	7.2	130
123	KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. International Journal of Oncology, 2016, 48, 1290-1296.	3.3	30
124	Clinician Perspective on Molecular Profiling of Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 884-886.	1.6	5
125	Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of Oncology, 2016, 27, 423-429.	1.2	51
126	Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture. Assay and Drug Development Technologies, 2016, 14, 19-28.	1.2	85

#	Article	IF	Citations
127	First-Line Afatinib versus Chemotherapy in Patients with Nonâ€“Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of Thoracic Oncology, 2016, 11, 380-390.	1.1	300
128	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. Journal of Clinical Oncology, 2016, 34, 9046-9046.	1.6	11
129	Short term ex-vivo expansion of circulating head and neck tumour cells. Oncotarget, 2016, 7, 60101-60109.	1.8	48
130	SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer. Oncotarget, 2016, 7, 72807-72818.	1.8	26
131	Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients. Molecular and Clinical Oncology, 2015, 3, 1073-1079.	1.0	3
132	Neoadjuvant Crizotinib in Advanced Inflammatory Myofibroblastic Tumour with ALK Gene Rearrangement. Tumori, 2015, 101, e35-e39.	1.1	12
133	Stimulating immune responses to fight cancer: Basic biology and mechanisms. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 9-15.	1.1	9
134	hSSB1 (NABP2/ OBFC2B) is required for the repair of 8-oxo-guanine by the hOGG1-mediated base excision repair pathway. Nucleic Acids Research, 2015, 43, 8817-8829.	14.5	37
135	The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treatment Reviews, 2015, 41, 160-169.	7.7	83
136	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, The, 2015, 16, 141-151.	10.7	1,369
137	Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Annals of Oncology, 2015, 26, 1734-1740.	1.2	55
138	Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. Molecular Cancer, 2015, 14, 45.	19.2	64
139	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 2015, 26, 1573-1588.	1.2	308
140	VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach. Epigenomics, 2015, 7, 897-910.	2.1	12
141	Tumour islet Foxp3⁺ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. European Respiratory Journal, 2015, 46, 1762-1772.	6.7	56
142	Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer. Molecular BioSystems, 2015, 11, 743-752.	2.9	33
143	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8073-8073.	1.6	6
144	Identifying driver mutations in squamous cell lung cancer (SCC): The Lung Cancer Genomics Ireland (LCGI) study.. Journal of Clinical Oncology, 2015, 33, 11078-11078.	1.6	0

#	Article	IF	Citations
145	Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 11077-11077.	1.6	0
146	The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e100816.	2.5	36
147	NÃ©stor-Guillermo Progeria Syndrome: a biochemical insight into Barrier-to-Autointegration Factor 1, alanine 12 threonine mutation. BMC Molecular Biology, 2014, 15, 27.	3.0	38
148	Prognostic impact of vascular and lymphovascular invasion in early lung cancer. Asian Cardiovascular and Thoracic Annals, 2014, 22, 55-64.	0.5	31
149	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	1.2	210
150	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology, 2014, 32, 2780-2787.	1.6	163
151	National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 11-17.	1.1	11
152	The Establishment of an ISO Compliant Cancer Biobank for Jordan and its Neighboring Countries Through Knowledge Transfer and Training. Biopreservation and Biobanking, 2014, 12, 3-12.	1.0	10
153	Strategic targeting of the PI3Kâ€“NFÎºB axis in cisplatin-resistant NSCLC. Cancer Biology and Therapy, 2014, 15, 1367-1377.	3.4	23
154	Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 717-724.	1.1	50
155	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	1.2	246
156	Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising. Frontiers in Oncology, 2014, 4, 86.	2.8	100
157	Functions and Therapeutic Roles of Exosomes in Cancer. Frontiers in Oncology, 2014, 4, 127.	2.8	210
158	Lungscape: Resected Nonâ€“Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. Journal of Thoracic Oncology, 2014, 9, 1675-1684.	1.1	31
159	Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treatment Reviews, 2014, 40, 445-456.	7.7	143
160	High Coexpression of Both EGFR and IGF1R Correlates With Poor Patient Prognosis in Resected Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 58-66.	2.6	44
161	Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer, 2014, 83, 211-218.	2.0	64
162	Predictive Values for Molecular Diagnostics: Converting Unknown Unknowns to Known Unknowns. Molecular Diagnosis and Therapy, 2014, 18, 1-4.	3.8	2

#	Article	IF	Citations
163	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, 1462-1474.	1.2	410
164	The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treatment Reviews, 2014, 40, 1161-1170.	7.7	114
165	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 1369-1378.	10.7	124
166	DNA repair pathways and their therapeutic potential in lung cancer. Lung Cancer Management, 2014, 3, 159-173.	1.5	10
167	Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience. European Archives of Oto-Rhino-Laryngology, 2014, 271, 2253-2259.	1.6	19
168	Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 747-755.	3.8	21
169	Trastuzumab (T) and pertuzumab (P)-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) in tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines.. Journal of Clinical Oncology, 2014, 32, 643-643.	1.6	3
170	Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre. Irish Journal of Medical Science, 2013, 182, 217-225.	1.5	4
171	Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. Cell Death and Disease, 2013, 4, e951-e951.	6.3	59
172	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology, 2013, 31, 3327-3334.	1.6	2,854
173	Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology, 2013, 31, 3342-3350.	1.6	285
174	Human single-stranded DNA binding proteins are essential for maintaining genomic stability. BMC Molecular Biology, 2013, 14, 9.	3.0	85
175	Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	27.0	3,181
176	IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer, 2013, 79, 83-90.	2.0	33
177	RanGTPase: A Candidate for Myc-Mediated Cancer Progression. Journal of the National Cancer Institute, 2013, 105, 475-488.	6.3	33
178	Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy. Frontiers in Oncology, 2013, 3, 120.	2.8	225
179	IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2013, 3, 162.	2.8	15
180	Genome Stability Pathways in Head and Neck Cancers. International Journal of Genomics, 2013, 2013, 1-19.	1.6	18

#	Article	IF	Citations
181	Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biology and Therapy, 2013, 14, 1104-1112.	3.4	66
182	Estrogen receptor Î² activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis, 2013, 2, e72-e72.	4.9	34
183	MARS: A Sense of Perspective and an Inconvenient Truth. Journal of Thoracic Oncology, 2013, 8, e48-e49.	1.1	13
184	Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial. Journal of Thoracic Oncology, 2013, 8, 930-939.	1.1	56
185	Epigenetic Regulation of Chemokine/Chemokine Receptor Expression. Methods in Molecular Biology, 2013, 1013, 185-201.	0.9	1
186	Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature. PLoS ONE, 2013, 8, e54193.	2.5	221
187	Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS ONE, 2013, 8, e70940.	2.5	33
188	Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways. Clinical Cancer Research, 2012, 18, 380-391.	7.0	69
189	Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2012, 7, 1466-1470.	1.1	50
190	Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort. European Respiratory Journal, 2012, 40, 177-184.	6.7	92
191	The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1. Journal of Clinical Pathology, 2012, 65, 1-7.	2.0	34
192	Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death and Disease, 2012, 3, e449-e449.	6.3	35
193	Bone matters in lung cancer. Annals of Oncology, 2012, 23, 2215-2222.	1.2	50
194	The Cancer Stem-Cell Hypothesis: Its Emerging Role in Lung Cancer Biology and Its Relevance for Future Therapy. Journal of Thoracic Oncology, 2012, 7, 1880-1890.	1.1	124
195	Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. International Journal of Molecular Medicine, 2012, 30, 1505-1511.	4.0	31
196	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer, 2012, 76, 19-25.	2.0	153
197	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncology, The, 2012, 13, 33-42.	10.7	526
198	A STEPP too far for FLEX? â€“ Authors' reply. Lancet Oncology, The, 2012, 13, e51.	10.7	0

#	Article	IF	Citations
199	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. European Journal of Cancer, 2012, 48, 2983-2992.	2.8	30
200	Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 500-504.	2.6	85
201	Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland. Irish Journal of Medical Science, 2012, 181, 451-452.	1.5	1
202	BRCA1 is an essential mediator of vinorelbineâ€induced apoptosis in mesothelioma. Journal of Pathology, 2012, 227, 200-208.	4.5	33
203	Analysis of acuteâ€phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. International Journal of Cancer, 2012, 131, 911-923.	5.1	61
204	A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. Irish Journal of Medical Science, 2012, 181, 211-214.	1.5	6
205	COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 49-63.	7.4	33
206	Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: Lessons from the experience of a high-volume center. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 1130-1137.e1.	0.8	36
207	Ipilimumab-induced immune-related renal failure--a case report. Anticancer Research, 2012, 32, 4607-8.	1.1	49
208	IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. European Journal of Cancer, 2011, 47, 1908-1918.	2.8	36
209	First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncology, The, 2011, 12, 30-37.	10.7	113
210	Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncology, The, 2011, 12, 763-772.	10.7	612
211	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncology, The, 2011, 12, 795-805.	10.7	199
212	The MARS feasibility trial: conclusions not supported by data â€" Authors' reply. Lancet Oncology, The, 2011, 12, 1094-1095.	10.7	26
213	Receptor tyrosine kinases and their activation in melanoma. Pigment Cell and Melanoma Research, 2011, 24, 446-461.	3.3	69
214	Epigenetics Underpinning the Regulation of the CXC (ELR+) Chemokines in Non-Small Cell Lung Cancer. PLoS ONE, 2011, 6, e14593.	2.5	44
215	Fifty years of Sudanese hospital-based obstetric outcomes and an international partnership. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 1608-1616.	2.3	7
216	A Role for IGF-1Râ€"Targeted Therapies in Small-Cell Lung Cancer?. Clinical Lung Cancer, 2011, 12, 38-42.	2.6	8

#	Article	IF	Citations
217	Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Molecular Cancer, 2011, 10, 25.	19.2	49
218	PARP inhibition induces BAX/BAKâ€independent synthetic lethality of BRCA1â€deficient nonâ€small cell lung cancer. Journal of Pathology, 2011, 224, 564-574.	4.5	32
219	Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer. Cancer, 2011, 117, 5121-5132.	4.1	23
220	An Extracellular Signalâ€“Regulated Kinase 2 Survival Pathway Mediates Resistance of Human Mesothelioma Cells to Asbestos-Induced Injury. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 906-914.	2.9	14
221	The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. Cancers, 2011, 3, 1426-1453.	3.7	35
222	Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer. Cancers, 2011, 3, 1550-1565.	3.7	26
223	Design, Construction, and Analysis of Cell Line Arrays and Tissue Microarrays for Gene Expression Analysis. Methods in Molecular Biology, 2011, 784, 139-153.	0.9	11
224	Differential Pathologic Variables and Outcomes across the Spectrum of Adenocarcinoma of the Esophagogastric Junction. World Journal of Surgery, 2010, 34, 2821-2829.	1.6	28
225	The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 153-166.	7.4	35
226	A Lung Cancer Responding to Hormonal Therapy. Journal of Thoracic Oncology, 2010, 5, 749-750.	1.1	4
227	Assessing support requirements for multidisciplinary team meetings. , 2010, , .		6
228	Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor. Acta OncolÃ³gica, 2010, 49, 872-874.	1.8	8
229	The Role of Inflammation in the Pathogenesis of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 2024-2036.	1.1	243
230	Targeting oxidative stress in cancer. Expert Opinion on Therapeutic Targets, 2010, 14, 1225-1245.	3.4	58
231	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. European Respiratory Journal, 2009, 34, 1477-1486.	6.7	15
232	Targeting histone deacetylases for the treatment of disease. Journal of Cellular and Molecular Medicine, 2009, 13, 826-852.	3.6	41
233	Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. Journal of Cellular and Molecular Medicine, 2009, 13, 2800-2821.	3.6	86
234	Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death and Differentiation, 2009, 16, 1352-1361.	11.2	40

#	Article	IF	Citations
235	Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. European Journal of Cancer, 2009, 45, 3087-3097.	2.8	23
236	Cisplatin and gemcitabine in the management of metastatic penile cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 187-190.	1.6	27
237	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, The, 2009, 373, 1525-1531.	13.7	1,321
238	Gene Expression Analysis of Diagnostic Biopsies Predicts Pathological Response to Neoadjuvant Chemoradiotherapy of Esophageal Cancer. Annals of Surgery, 2009, 250, 729-737.	4.2	71
239	The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study. Journal of Thoracic Oncology, 2009, 4, 1254-1258.	1.1	80
240	Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials. Journal of Thoracic Oncology, 2009, 4, 869-874.	1.1	68
241	In Arrayed Ranks: Array Technology in the Study of Mesothelioma. Journal of Thoracic Oncology, 2009, 4, 411-425.	1.1	16
242	Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?. Current Diabetes Reviews, 2009, 5, 201-209.	1.3	15
243	Gene Expression Profiling of Human Adipocyte Responses to Insulin and IGF-I Signalling. The Open Diabetes Journal, 2009, 2, 5-17.	0.4	2
244	Transcriptional Regulation of IRS5/DOK4 Expression in Nonâ€“Small-Cell Lung Cancer Cells. Clinical Lung Cancer, 2008, 9, 367-374.	2.6	7
245	Advances in the systemic therapy of malignant pleural mesothelioma. Nature Clinical Practice Oncology, 2008, 5, 136-147.	4.3	124
246	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Annals of Oncology, 2008, 19, 362-369.	1.2	247
247	Cyclooxygenase-2-Linked Attenuation of Hypoxia-Induced Pulmonary Hypertension and Intravascular Thrombosis. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 51-58.	2.5	37
248	Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-NaÃ¯ve Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 623-630.	1.1	188
249	Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Annals of Surgery, 2007, 245, 707-716.	4.2	139
250	Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 3266-3273.	1.6	46
251	Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer, 2007, 56, 459-463.	2.0	39
252	DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma. International Journal of Cancer, 2007, 121, 992-998.	5.1	7

#	Article	IF	Citations
253	Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology Biology Physics, 2007, 69, 167-175.	0.8	111
254	Lipoxygenase metabolism: roles in tumor progression and survival. Cancer and Metastasis Reviews, 2007, 26, 503-524.	5.9	247
255	B2-04: Single agent versus combination therapy in advanced NSCLC patients with performance status 2: Results from a regression analysis of STELLAR 3 and 4. Journal of Thoracic Oncology, 2007, 2, S337-S338.	1.1	1
256	Inflammation and Cancer. Cancer Treatment and Research, 2006, , 1-38.	0.5	58
257	18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. British Journal of Cancer, 2006, 95, 1174-1179.	6.4	125
258	Interactions Between Hypoxia and Epidermal Growth Factor Receptor in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2006, 7, 250-256.	2.6	80
259	PIONEER: A Phase III Randomized Trial of Paclitaxel Poliglumex Versus Paclitaxel in Chemotherapy-Naive Women with Advanced-Stage Non-Small-Cell Lung Cancer and Performance Status of 2. Clinical Lung Cancer, 2006, 7, 417-419.	2.6	52
260	A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Annals of Oncology, 2006, 17, 1111-1119.	1.2	57
261	An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Nonâ€“Small Cell Lung Cancers. Clinical Cancer Research, 2006, 12, 1507-1514.	7.0	237
262	Phospho-Akt Expression Is Associated with a Favorable Outcome in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 2930-2936.	7.0	87
263	Macrophage and Mast-Cell Invasion of Tumor Cell Islets Confers a Marked Survival Advantage in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 8959-8967.	1.6	330
264	Expression of Thrombospondin-1 in Resected Colorectal Liver Metastases Predicts Poor Prognosis. Clinical Cancer Research, 2005, 11, 6567-6573.	7.0	30
265	Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege. Journal of Clinical Oncology, 2005, 23, 8932-8941.	1.6	233
266	Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group. Journal of Clinical Oncology, 2005, 23, 4265-4274.	1.6	1,435
267	SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Annals of Oncology, 2004, 15, 906-914.	1.2	126
268	The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2004, 25, 497-501.	1.4	53
269	Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. British Journal of Cancer, 2004, 91, 1301-1307.	6.4	50
270	Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L859-L865.	2.9	28

#	Article	IF	Citations
271	Management of endocrine resistant breast cancer. The Journal of the British Menopause Society, 2004, 10, 16-23.	1.3	2
272	Postoperative chemotherapy for nonâ€“small cell lung cancer: A systematic review and meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 414-419.	0.8	111
273	Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecologic Oncology, 2004, 94, 502-508.	1.4	31
274	Hypoxia-inducible factor-1? in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. International Journal of Cancer, 2004, 111, 43-50.	5.1	153
275	Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer, 2004, 45, S45-S48.	2.0	31
276	The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Annals of Thoracic Surgery, 2004, 78, 245-252.	1.3	62
277	Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treatment Reviews, 2004, 30, 53-81.	7.7	184
278	Malignant Pleural Mesotheliomaâ€"An Update. International Journal of Occupational and Environmental Health, 2004, 10, 26-39.	1.2	18
279	Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. International Journal of Biological Markers, 2004, 19, 262-267.	1.8	11
280	Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer. , 2003, 74, 357-374.		1
281	Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. Cancer Chemotherapy and Pharmacology, 2003, 52, 367-370.	2.3	14
282	Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer, 2003, 98, 542-553.	4.1	79
283	Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. British Journal of Cancer, 2003, 88, 1553-1559.	6.4	63
284	Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer, 2003, 39, 1-13.	2.0	48
285	O-78 Microarray analysis of mesothelial cells treated with crocidolite, erionite, IL-1beta and TNF-alpha. Lung Cancer, 2003, 41, S25-S26.	2.0	1
286	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies. Journal of Clinical Oncology, 2003, 21, 3955-3964.	1.6	648
287	Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2003, 21, 473-482.	1.6	262
288	Tumor Necrosis Correlates With Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma *. Chest, 2003, 124, 1916-1923.	0.8	94

#	Article	IF	Citations
289	Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clinical Cancer Research, 2003, 9, 2583-6.	7.0	36
290	Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). Oncology Reports, 2003, 10, 1625-31.	2.6	16
291	A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. British Journal of Cancer, 2002, 87, 15-20.	6.4	64
292	Potential of Interferon-?? in Solid Tumours. BioDrugs, 2002, 16, 261-281.	4.6	50
293	Potential of Interferon-?? in Solid Tumours. BioDrugs, 2002, 16, 349-372.	4.6	30
294	Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer, 2002, 37, 235-240.	2.0	143
295	Reduced Thrombospondin-1 at Presentation Predicts Disease Progression in Superficial Bladder Cancer. European Urology, 2002, 42, 464-468.	1.9	25
296	A computer image analysis system for microvessel density measurement in solid tumours. Angiogenesis, 2002, 5, 15-20.	7.2	31
297	Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clinical Cancer Research, 2002, 8, 1857-62.	7.0	60
298	Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer, 2001, 34, 417-426.	2.0	22
299	Intramedullary spinal cord metastasis. Lancet Oncology, The, 2001, 2, 607.	10.7	10
300	Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncology, The, 2001, 2, 726-732.	10.7	69
301	Infection and cancer. Lancet, The, 2001, 358, 156.	13.7	3
302	Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. Cancer Chemotherapy and Pharmacology, 2001, 48, 197-201.	2.3	3
303	A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2001, 48, 266-268.	2.3	16
304	The use of microvessel density in assessing human urological tumours. BJU International, 2001, 87, 866-875.	2.5	14
305	Herceptest: Her2 expression and gene amplification in non-small cell lung cancer. International Journal of Cancer, 2001, 92, 480-483.	5.1	77
306	Angiogenesis is an independent prognostic factor in malignant mesothelioma. British Journal of Cancer, 2001, 85, 863-868.	6.4	97

#	Article	IF	Citations
307	Chronic immune activation and inflammation as the cause of malignancy. British Journal of Cancer, 2001, 85, 473-483.	6.4	459
308	Familiar drugs may prevent cancer. Postgraduate Medical Journal, 2001, 77, 492-497.	1.8	4
309	â€˜Invading edge vs. innerâ€™ (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. Journal of Pathology, 2000, 192, 140-149.	4.5	57
310	Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. British Journal of Cancer, 2000, 82, 1427-1432.	6.4	252
311	Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. British Journal of Cancer, 2000, 82, 1776-1782.	6.4	4
312	Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. British Journal of Cancer, 2000, 82, 1759-1763.	6.4	15
313	Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. British Journal of Cancer, 2000, 83, 219-224.	6.4	14
314	Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. Cancer Chemotherapy and Pharmacology, 2000, 45, 111-119.	2.3	19
315	Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax, 2000, 55, 731-735.	5.6	279
316	Chemotherapy for upper gastrointestinal tumours. Postgraduate Medical Journal, 2000, 76, 321-321.	1.8	8
317	Evolution, immune response, and cancer. Lancet, The, 2000, 356, 1033-1034.	13.7	10
318	Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Annals of Diagnostic Pathology, 2000, 4, 286-292.	1.3	15
319	A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Annals of Oncology, 1999, 10, 981-983.	1.2	5
320	The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax, 1999, 54, 169-179.	5.6	53
321	Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. British Journal of Cancer, 1999, 79, 1413-1418.	6.4	36
322	bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clinical and Experimental Metastasis, 1999, 17, 545-554.	3.3	48
323	Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemotherapy and Pharmacology, 1999, 44, 453-460.	2.3	86
324	Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet, The, 1999, 353, 1494-1495.	13.7	58

#	Article	IF	Citations
325	Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. British Journal of Cancer, 1998, 77, 1696-1703.	6.4	103
326	Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. British Journal of Cancer, 1998, 77, 1950-1956.	6.4	10
327	The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas. Critical Reviews in Oncology/Hematology, 1998, 27, 221-227.	4.4	12
328	A phase II study of bryostatin 1 in metastatic malignant melanoma. British Journal of Cancer, 1998, 78, 1337-1341.	6.4	70
329	Phase I study of the mitomycin C analogue BMS-181174. British Journal of Cancer, 1998, 77, 2020-2027.	6.4	5
330	A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Annals of Oncology, 1998, 9, 1205-1211.	1.2	15
331	A Novel Cyclic Adenosine Monophosphate Analog Induces Hypercalcemia via Production of 1,25-Dihydroxyvitamin D in Patients with Solid Tumors. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4044-4048.	3.6	25
332	Extrapulmonary Small Cell Gastric Carcinoma:A Case Report and Review of the Literature. Acta OncolÃ³gica, 1997, 36, 78-80.	1.8	37
333	A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Annals of Oncology, 1997, 8, 294-296.	1.2	6
334	Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.. Journal of Clinical Oncology, 1997, 15, 3185-3191.	1.6	292
335	Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. British Journal of Cancer, 1997, 75, 477-481.	6.4	126
336	Molecular approaches to diagnosis and management of ovarian cancer. Cancer and Metastasis Reviews, 1997, 16, 81-107.	5.9	15
337	Platelet-derived endothelial cell growth factor (Thymidine Phosphorylase) expression in lung cancer. , 1997, 181, 196-199.		50
338	Potential role ofbcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. , 1997, 74, 565-570.		54
339	Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.. Journal of Clinical Oncology, 1996, 14, 1903-1912.	1.6	24
340	Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. British Journal of Cancer, 1996, 73, 1161-1165.	6.4	16
341	PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER. Journal of Pathology, 1996, 179, 80-88.	4.5	144
342	Endoscopic papillectomy: a novel approach to difficult cannulation.. Gut, 1996, 39, 36-38.	12.1	35

#	Article	IF	Citations
343	Imaging of bronchial carcinoid tumours with indium-111 pentetreotide.. Thorax, 1994, 49, 284-286.	5.6	16
344	A metastatic neuroendocrine anaplastic small cell tumor in a patient with multiple endocrine neoplasia type 1 syndrome. Assessment of disease status and response to doxorubicin, cyclophosphamide, etoposide chemotherapy through scintigraphic imaging with111in-pentetreotide. Cancer, 1994, 74, 2374-2378.	4.1	10
345	Irish association for cancer research. Irish Journal of Medical Science, 1994, 163, 341-354.	1.5	0
346	Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. British Journal of Cancer, 1994, 70, 886-892.	6.4	33
347	Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue. British Journal of Cancer, 1994, 69, 762-766.	6.4	37
348	Irish society of gastroenterology. Irish Journal of Medical Science, 1993, 162, 513-528.	1.5	0
349	Imaging of medullary carcinoma of the thyroid using 111In-labelled anti-CEA monoclonal antibody fragments. Nuclear Medicine Communications, 1992, 13, 142-148.	1.1	19
350	The Prognostic Significance of Circulating Tumour Cells in Head and Neck and Non-Small Cell Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	1
351	COMMD4 Functions with the Histone H2A-H2B Dimer for the Timely Repair of DNA Double Strand Breaks. SSRN Electronic Journal, 0, , .	0.4	3
352	Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (Review). Oncology Reports, 0, , .	2.6	9